- Home
- LXRX vs RCKT Comparison
LXRX vs RCKT Comparison
Compare LXRX & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LXRX | RCKT |
|---|---|---|
| Founded | 1995 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 465.2M | 428.6M |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | LXRX | RCKT |
|---|---|---|
| Price | $1.31 | $3.25 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 14 |
| Target Price | $3.23 | ★ $30.27 |
| AVG Volume (30 Days) | ★ 4.1M | 2.1M |
| Earning Date | 03-05-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $70,864,000.00 | N/A |
| Revenue This Year | $56.61 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1255.21 | N/A |
| 52 Week Low | $0.28 | $2.19 |
| 52 Week High | $1.83 | $11.11 |
Technical Indicators
Market Signals| Indicator | LXRX | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 49.20 | 41.54 |
| Support Level | $1.17 | $3.07 |
| Resistance Level | $1.39 | $3.32 |
| Average True Range (ATR) | 0.14 | 0.19 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 33.61 | 33.11 |
Price Performance
Historical ComparisonAbout LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.